By the Top Tier Newswire AI Desk · October 23, 2026 at 12:03 AM ET · reviewed against 50 wire stories
MODERNA INC (MRNA) is down -17.57% in the latest session. Our newswire has captured 50 stories on MRNA across 24 sources in the last 36 hours, with AI sentiment reading bearish (avg 37/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Moderna shares fell 17.57% to $202.63, marking the company's worst week in three months. The primary driver was a leak of Phase 3 cancer vaccine data that failed to meet elevated Wall Street expectations, despite showing a 42% reduction in melanoma recurrence or death risk.
What Happened
The stock decline followed the premature release of trial results for Intismeran Autogene, a personalized mRNA cancer therapy developed with Merck. The data indicated that the combination of Intismeran and Keytruda cut the risk of melanoma recurrence or death by 42%. While the results were positive, analysts noted that the figures did not exceed the lofty expectations set by the market. Mizuho analyst Jared Holz stated that the drop reflected a high bar rather than bad data, describing the stock as a do-not-trade due to wild swings. The company is scheduled to present the full data at a conference on Saturday.
What The Data Shows
Moderna has a market capitalization of $96.6 billion and remains unprofitable, with a trailing twelve-month EPS of -8.01 and revenue down 27.6%. The stock's beta is 1.09, and it trades within a 52-week range of $22.28 to $254.48. On October 22, 2026, the stock printed one fresh 52-week high and 48 fresh 52-week lows. Unusual options activity over the last 36 hours included 75 notable prints, with put premium of $120.0 million exceeding call premium of $81.7 million. The largest single print was $22.4 million. Insider filings show five sells totaling $62.6 million in the last 90 days, with no buys. Recent sales include shares by President Stephen Hoge and CFO James M. Mock.
What To Watch
Investors will monitor the official presentation of the Phase 3 melanoma trial data scheduled for Saturday. The stock has moved 6.3% lower over the last eight sessions, falling from $216.25 to $202.63. Coverage breadth remains high, with 50 stories from 24 sources in the last 36 hours.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
MRNA · Oct 23 session (5-min) · -0.64% vs prior close · updated 8:29 PM ETAI sentiment, last 36h · averaged over 50 stories · 37/100 bearish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
1d agoMorningstarBEARISH 42General
Dow Jones Top Company Headlines at 11 PM ET: SK Hynix Shelves Memory-Chip Unit U.S. IPO Plan on Market Jitters | Moderna's ...
The company now expects full-year adjusted earnings of between $3.10 and $3.40 a share after reporting a profit of $250.3 million, driven by demand for the company's on-site power solutions.
1d agoStocktwits NewsBEARISH 34Analyst
MRNA Stock’s Vaccine Rally Cracks As Worst Week In 3 Months Looms — Analyst Calls It A ‘Do-Not-Trade’ Over Wild Swings
Mizuho analyst Jared Holz said the vaccine data weren’t bad, but Wall Street’s expectations were too high.
1d agoMorningstarNEUTRAL 50General
Dow Jones Top Company Headlines at 9 PM ET: SK Hynix Shelves Plans for U.S. Listing of Memory-Chip Unit Solidigm | Moderna's ...
The company now expects full-year adjusted earnings of between $3.10 and $3.40 a share after reporting a profit of $250.3 million, driven by demand for the company's on-site power solutions.
1d agoStocktwits NewsBEARISH 38General
Nasdaq 100 Clocks Worst Day In Four Months As Investors Grow Weary Of Capex, Elevated Debt — META, SPCX, BE, MRNA In Focus
Meta’s plan to boost capex reignited investor concerns as more tech firms look to raise debt to fund AI growth.
1d agoMorningstarBEARISH 22Earnings
Dow Jones Top Company Headlines at 7 PM ET: Moderna's Stock Plummets After Cancer-Vaccine Data Shared on Social Media | American ...
The company now expects full-year adjusted earnings of between $3.10 and $3.40 a share after reporting a profit of $250.3 million, driven by demand for the company's on-site power solutions.
1d agoCNBCNEUTRAL 52Analyst
Mizuho's Jared Holz: Moderna drop reflects high bar, not bad data
Jared Holz, Mizuho healthcare sector specialist, joins 'Fast Money' to talk the drop in Moderna's stock following new cancer vaccine data.
1d agoFinancial TimesBEARISH 34Earnings
Moderna shares sink after leaked cancer data missed expectations
Melanoma vaccine treatment cut risk of recurrence or death by 58% but failed to exceed Wall Street’s lofty expectations
1d agoMorningstarBEARISH 22Earnings
Dow Jones Top Company Headlines at 5 PM ET: Moderna's Stock Plummets After Cancer-Vaccine Data Shared on Social Media | American ...
The company now expects full-year adjusted earnings of between $3.10 and $3.40 a share after reporting a profit of $250.3 million, driven by demand for the company's on-site power solutions.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →